Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

essure alone and in combination with an ACE-I[5][6]. Further details about this proof-of-concept Phase II trial will be announced later in 2007 when it commences. The trial will be carried out in Europe with results due in the second half of 2008.

Speedel's next generation renin inhibitors include other compounds in the SPP600 series, the SPP1100 series with SPP1148 due to report first Phase I results in Q42007, and the SPP800 series currently in late-stage pre-clinical profiling. Each series is a different chemical class with distinct properties and is protected by different patent applications.


About SPP600 series
SPP635 is the most advanced compound of the SPP600 series of renin inhibitors being developed by Speedel. The company has made significant progress in the optimisation and development of this series of newly synthesised compounds by using rational drug design, including computer assisted molecular modelling techniques, state-of-the art preclinical disease models and human microdosing.

In December 2001, Speedel acquired a worldwide exclusive license from Roche covering its entire programme in renin inhibition. This license allows Speedel to use the acquired know-how for lead optimisation of its own compounds designated as the SPP600 series. Speedel holds full development and commercialization rights for these product candidates under the license agreement with Roche. If Speedel decides to offer rights to any Speedel compound from the series to a third party, Roche has a right of first negotiation with respect to such rights. If Roche has not expressed its interest in acquiring such rights within a defined period of time, or the parties have not reached an agreement on the terms of such rights, Speedel is free to grant such rights to any third party.

About Hypertension
Hypertension is a common disorder in which blood pressure is abnormally high, placing undue stress on the heart, b
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4
... 16, 2007 - Somanta,Pharmaceuticals (OTCBB:SMPM) today announced ... presented later today at the American,Association for ... The poster presentation is entitled "Cytotoxicity of ... Excision,Repair and DNA Mismatch Repair defects," and ...
... Second Half of 2007 -, BRISBANE, Australia, April ... the final stage 1,results of its Phase 2 ... surgical removal of liver cancer. The 48 week,data ... improvement in,disease-free rate, the primary endpoint, of 25 ...
Cached Medicine Technology:Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
(Date:9/1/2014)... involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) are ... where issues related to claims involving the pain reliever ... Bernstein Liebhard LLP reports. , According to a ... the meeting is scheduled to take place on September ... of several Tylenol conferences that have taken place this ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Developers of FCPX ... tutorial video for the ProWorld Plugin from Pixel Film Studios. ... Pro X can do and users now have the ability ... Said Christina Austin, CEO of Pixel Film Studios. “Blurring the ... changer.” , Learn how to turn a 2D HDRI image ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
... ... recorder prior to offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital ... professionals and everyday consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in ...
... has proved surprisingly effective at binding to the DNA of ... minutes. The DNA binding properties of the compound were first ... Warwick by Professor Mike Hannon and Professor Alison Rodger (Professor ... the strength of its antibiotic powers have now made it ...
... Widely Expressed on Tumors and Tumor Blood Vessel Cells ... Inc., a subsidiary of Eisai Corporation of North America, ... cleared its investigational new drug (IND) application to study ... MORAb-004 targets endosialin, a protein expressed on cells associated ...
... Will Increase by a Modest $300 Million From 2008 to ... , WALTHAM, Mass., June 9 Decision Resources, one ... and healthcare issues, finds that growth in the Parkinson,s disease ... through 2018, will be offset by generic erosion of key ...
... in Four Locations to Hold Discussions on Aging in Place ... , WASHINGTON, June 9 As part of a ... in America will be hosting workshops throughout the month of ... older Americans remain in their communities. , , ...
... America, Inc. (OTC Bulletin Board: CPCF), announced today that its ... application to the MedClose(TM) Vascular Closure System (VCS) -- previously ... and basis for its new strategic plan as a Closure ... and testing of the MedClose(TM) VCS, which is an internal ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 3Health News:How Prepared are America's Communities to Handle the Aging Boom? 4Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 2Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 3Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 4
This compression garment can be used for Breast Augmentation, Augmentation Mammaplasty, Trans Umbilical Breast Augmentation, Transaxillary Submuscular Augmentation....
Bra With Cups...
Bras and Breast Support...
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication...
Medicine Products: